Atomwise and Enamine to Advance Pediatric Oncology With the World’s First and Largest Ten Billion Compound Virtual Screen
Summary
SAN FRANCISCO & KIEV, Ukraine--(BUSINESS WIRE)--Atomwise, Inc. today announced the launch of a 10 billion compound AI-powered virtual drug screening initiative, the 10-to-the-10 program, in collaboration with Enamine Ltd., the world’s largest chemical supplier. The enormous screen in the 10-to-the-10 program is possible because of a confluence of technologies: accurate and rapid structure-based drug development with Atomwise’s AI algorithms, scalable cloud computing innovations, and large virtual libraries like Enamine’s REAL (readily accessible) database of compounds that can be synthesized quickly. “We’ve barely scratched the surface of what is possible – imagine what will be found when we screen a chemical library that is a thousand times larger.” With Atomwise, partners have reported early preclinical success rates more than twice the industry standard. With the 10-to-the-10 program, researchers will be able to efficiently test a large and diverse set of compounds, which enables the early identification of solutions to potential roadblocks in drug development. Dr. Pengda Liu at the University of North Carolina Lineberger Comprehensive Cancer Center, who has had success with Atomwise’s AIMS Awards, is hoping to take advantage of this program to advance his research.